65G Stock Overview
A biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
NextCell Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.26 |
| 52 Week High | SEK 0.29 |
| 52 Week Low | SEK 0.063 |
| Beta | 0.53 |
| 1 Month Change | 56.97% |
| 3 Month Change | 128.19% |
| 1 Year Change | 48.00% |
| 3 Year Change | -60.94% |
| 5 Year Change | n/a |
| Change since IPO | -87.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 65G | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.2% | -3.2% | 2.7% |
| 1Y | 48.0% | -7.9% | 17.0% |
Return vs Industry: 65G exceeded the German Biotechs industry which returned -7.9% over the past year.
Return vs Market: 65G exceeded the German Market which returned 17% over the past year.
Price Volatility
| 65G volatility | |
|---|---|
| 65G Average Weekly Movement | 16.6% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 65G's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 65G's weekly volatility has decreased from 46% to 17% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 24 | Mathias Svahn | www.nextcellpharma.com |
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank.
NextCell Pharma AB Fundamentals Summary
| 65G fundamental statistics | |
|---|---|
| Market cap | €21.62m |
| Earnings (TTM) | -€3.58m |
| Revenue (TTM) | €841.83k |
25.7x
P/S Ratio-6.0x
P/E RatioIs 65G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 65G income statement (TTM) | |
|---|---|
| Revenue | SEK 9.45m |
| Cost of Revenue | SEK 15.06m |
| Gross Profit | -SEK 5.61m |
| Other Expenses | SEK 34.59m |
| Earnings | -SEK 40.21m |
Last Reported Earnings
Nov 30, 2024
Next Earnings Date
Apr 25, 2025
| Earnings per share (EPS) | -0.55 |
| Gross Margin | -59.42% |
| Net Profit Margin | -425.55% |
| Debt/Equity Ratio | 0% |
How did 65G perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 19:08 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/11/30 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NextCell Pharma AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Filip Einarsson | Redeye |